Trump accuses FDA of thwarting coronavirus response, after admin limits testing oversight
Add Axios as your preferred source to
see more of our stories on Google.
President Trump at the White House on Aug 20. Photo: Jabin Botsford/The Washington Post via Getty Images
President Trump on Saturday baselessly accused the Food and Drug Administration — which he likened to the "deep state, or whoever" — of making it harder for drug companies to distribute coronavirus treatments and vaccines.
Why it matters: Trump's tweet comes on the heels of a policy change by the Department of Health and Human Services to block the FDA's ability to regulate lab-developed tests, including for the coronavirus — which has public health experts worried that unreliable COVID-19 tests could go to market.
- The HHS said Friday that it moved to prohibit the FDA from overseeing tests as part of a broader Trump administration review of "duplicative actions and unnecessary policies."
Where it stands: The FDA has authorized 218 coronavirus tests with emergency use authorizations as of Friday, which includes 176 molecular tests, 39 antibody tests, and 3 antigen tests, the agency said.
- Philip Dormitzer, Pfizer’s head of vaccine research, told Bloomberg on Friday that trials are "going very quickly."
What they're saying: "For the last 6 months, FDA’s device center worked effectively with labs to advance hundreds of tests for Covid," former FDA Commissioner Scott Gottlieb, who served under Trump, tweeted roughly an hour after the president on Saturday morning.
- But, Gottlieb noted that the "FDA might not be able to provide critical advice to test developers or take needed enforcement actions against bad tests" since the HHS took the reins this week.
- "We'll see a plethora of DTC Covid tests enter the market, where tests ship directly to consumers and are processed in a central lab operating outside FDA oversight," Gottlieb said.
- House Speaker Nancy Pelosi called Trump's tweet "a very dangerous statement" at her Saturday press briefing and said that "even for him, it went beyond the pale."
Between the lines: The policy change surprised many at the FDA and "was a point of intense disagreement" between FDA Commissioner Stephen Hahn and HHS Secretary Alex Azar, the Washington Post reports. Hahn opposed the change.
The other side: Supporters said the change, announced Wednesday, could allow innovative tests to reach the public more efficiently, and countered that the FDA's process slowed testing at the start of the pandemic, per the Post.
- “This deregulatory action ensures compliance with law, is responsive to multiple Trump Administration Executive Orders, is a key lesson learned, and better prepares us for future pandemics," HHS chief of staff Brian Harrison said in an emailed statement.
- “It is false to say that this will lead to unregulated, low quality COVID-19 tests," HHS general counsel Robert Charrow emailed.
The FDA did not respond to a request for comment. The White House declined to comment.
